Is XOMA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,126 people get XOMA articles and Market Currents by email alert.

Get email alerts on XOMA »

HEADLINES:

XOMA Management Presents at Credit Suisse 2013 Antibody Day (Transcript)
Fri, May 10
XOMA Corp CEO Discuses Q1 2013 Results - Earnings Call Transcript
Wed, May 8 • 2 Comments
XOMA Highlights Recent Achievements and Reports Financial Results for First Quarter 2013

GlobeNewswire (May 8, 2013)
XOMA to Present at Credit Suisse 2013 Antibody Day

GlobeNewswire (May 6, 2013)
XOMA to Announce First Quarter 2013 Financial Results and Host Webcast on May 8

GlobeNewswire (Apr 25, 2013)
3 Highly Shorted Stocks Being Bought By Insiders
Kapitall • Thu, Apr 18 • 5 Comments
XOMA Announces Clinical Study Investigating Gevokizumab in Patients With Non-Infectious Anterior Scleritis Has Opened for Enrollment at the National Eye Institute

GlobeNewswire (Apr 10, 2013)
XOMA Appoints Tom Klein to Newly Created Position of Chief Commercial Officer

GlobeNewswire (Mar 18, 2013)
XOMA's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
XOMA Reports 2012 Operational Highlights and Fourth Quarter and Full-Year Financial Results

GlobeNewswire (Mar 12, 2013)
XOMA Announces Fourth Quarter and Full-Year Financial Results Conference Call

GlobeNewswire (Mar 4, 2013)
XOMA to Present at Upcoming Investor Conferences

GlobeNewswire (Feb 21, 2013)
XOMA: Will The Love-Hate Marriage With Investors Finally End Up In A Stable Relationship?
Prohost Biotech • Wed, Jan 16 • 4 Comments
XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris

GlobeNewswire (Jan 7, 2013)
Exclusive Interview With John Varian, XOMA Corporation CEO
Ben Yoffe • Thu, Jan 3 • 2 Comments
XOMA Selects Non-Infectious Anterior Scleritis as Next Indication in Gevokizumab Proof-of-Concept Program

GlobeNewswire (Dec 31, 2012)
XOMA Appoints Joseph M. Limber to Its Board of Directors

GlobeNewswire (Dec 13, 2012)
XOMA Announces Servier Has Initiated a Proof-of-Concept Gevokizumab Study in Patients With a History of Acute Coronary Syndrome

GlobeNewswire (Nov 29, 2012)
XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial

GlobeNewswire (Nov 20, 2012)
XOMA's CEO Presents at Credit Suisse Healthcare Conference (Transcript)
Thu, Nov 15, 2012

To learn more about Seeking Alpha Pro, click here.

XOMA: Will The Love-Hate Marriage With Investors Finally End Up In A Stable Relationship?
Prohost Biotech • Wed, Jan 16 • 4 Comments
Exclusive Interview With John Varian, XOMA Corporation CEO
Ben Yoffe • Thu, Jan 3 • 2 Comments
Xoma's New Plans Bring Hesitant Hope
Prohost Biotech • Wed, Jan 25, 2012 • 3 Comments
Is XOMA a Turnaround Stock?
Michael Bryant • Wed, Jan 12, 2011 • 20 Comments
Xoma Lands Deep-Pocketed French Partner
The Burrill Report • Sun, Jan 9, 2011 • 18 Comments
Xoma: Not Encouraged by All the Hoopla
Timeless Wealth • Mon, Dec 27, 2010 • 34 Comments
Xoma Rally Not a Surprise
Prohost Biotech • Wed, Dec 22, 2010 • 44 Comments
Xoma's Past, Present and Future
Prohost Biotech • Mon, Feb 15, 2010 • 11 Comments
Friday's BioPlay: Xoma Ltd.
M. E. Garza • Fri, Jun 5, 2009 • 2 Comments

3 Highly Shorted Stocks Being Bought By Insiders
Kapitall • Thu, Apr 18 • 5 Comments
Top 5 Stocks With Insider Buys Filed During The Week Ending November 2
Markus Aarnio • Sat, Nov 3, 2012 • 6 Comments
9 Highly Shorted Stocks Under $5 Being Bought By Hedge Funds
Kapitall • Thu, Aug 9, 2012 • 1 Comment
Hedge Funds Are Buying These 10 High-Growth Biotech Stocks
Kapitall • Sat, Jul 14, 2012
All-Star Stocks
Markos Kaminis • Wed, Jul 11, 2012 • 8 Comments
Micro Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
GuruFundPicks • Wed, Jul 11, 2012 • 9 Comments
An Assault On Vertex, Enthusiasm Building Around Xoma
Prohost Biotech • Fri, Jul 6, 2012 • 7 Comments
Russell 3000 U.S. Healthcare Additions For June 2012
EXPstocktrader • Mon, Jun 11, 2012 • 2 Comments
Biotech-Focused Baker Bros. $3.7B Fund Bought These 3 Big Winners And Sold Others In Q1
GuruFundPicks • Thu, May 17, 2012 • 9 Comments
4 Outperforming Small Caps Under $5 With Strong Receivable Trends
Kapitall • Fri, May 11, 2012
3 High-Growth Biotech Stocks With Bearish Short Trends
Kapitall • Thu, May 3, 2012 • 2 Comments
4 Rallying Micro Caps Under $5 With Positive Receivables Trends
Kapitall • Fri, Apr 20, 2012
Top Micro Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 12 Comments
5 Best Performing High Beta Biotechs
Kinetic Investments • Mon, Mar 26, 2012 • 9 Comments
Noteworthy Institutional 5% Ownership Filings Last Week
GuruFundPicks • Mon, Mar 19, 2012 • 1 Comment
Analysis Of Monday's Noteworthy Institutional 5% Ownership Filings In Healthcare
GuruFundPicks • Wed, Mar 14, 2012 • 3 Comments
The 5 Best Performing High Risk/Reward Biotech Stocks Of 2012
Kinetic Investments • Mon, Mar 12, 2012 • 6 Comments
10 Biotech Stocks Trading At The Deepest Discounts To Target Price
Kapitall • Wed, Nov 30, 2011 • 1 Comment
20 Healthcare Stocks Deeply Undervalued By Target Price
Kapitall • Wed, Nov 23, 2011 • 2 Comments
20 Healthcare Stocks With Positive Receivables Trends
Kapitall • Wed, Nov 16, 2011 • 1 Comment

XOMA Management Presents at Credit Suisse 2013 Antibody Day (Transcript)
Fri, May 10
XOMA Corp CEO Discuses Q1 2013 Results - Earnings Call Transcript
Wed, May 8 • 2 Comments
XOMA's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
XOMA's CEO Presents at Credit Suisse Healthcare Conference (Transcript)
Thu, Nov 15, 2012
XOMA's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012
XOMA's CEO Discusses Safety and Efficacy Study of Gevokizumab in Patients With Non-Infectious Uveitis Currently Controlled by Systemic Treatment Conference Call (Transcript)
Thu, Oct 4, 2012 • 1 Comment
XOMA's Management Presents at Morgan Stanley Global Healthcare Conference (Transcript)
Wed, Sep 12, 2012
XOMA's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 7, 2012
XOMA's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, May 8, 2012
XOMA's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Mar 14, 2012
XOMA's CEO Presents at the Eighth Annual Lazard Capital Markets Healthcare Conference - Conference Call Transcript
Wed, Nov 16, 2011
XOMA's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Wed, Nov 9, 2011
XOMA CEO Discusses Q2 2011 Results - Earnings Call Transcript
Thu, Aug 4, 2011
XOMA's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Fri, May 6, 2011
XOMA CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Mar 10, 2011
XOMA Management Discusses Q3 2010 Results- Earning Call Transcript
Thu, Nov 4, 2010 • 5 Comments
XOMA Ltd. Q2 2010 Earnings Call Transcript
Mon, Aug 9, 2010 • 3 Comments
XOMA Ltd. Q1 2010 Earnings Call Transcript
Fri, May 7, 2010
XOMA Ltd. Q4 2009 Earnings Call Transcript
Thu, Mar 11, 2010
XOMA Ltd. Q3 2009 Earnings Call Transcript
Mon, Nov 9, 2009

XOMA Highlights Recent Achievements and Reports Financial Results for First Quarter 2013

GlobeNewswire (May 8, 2013)
XOMA to Present at Credit Suisse 2013 Antibody Day

GlobeNewswire (May 6, 2013)
XOMA to Announce First Quarter 2013 Financial Results and Host Webcast on May 8

GlobeNewswire (Apr 25, 2013)
XOMA Announces Clinical Study Investigating Gevokizumab in Patients With Non-Infectious Anterior Scleritis Has Opened for Enrollment at the National Eye Institute

GlobeNewswire (Apr 10, 2013)
XOMA Appoints Tom Klein to Newly Created Position of Chief Commercial Officer

GlobeNewswire (Mar 18, 2013)
XOMA Reports 2012 Operational Highlights and Fourth Quarter and Full-Year Financial Results

GlobeNewswire (Mar 12, 2013)
XOMA Announces Fourth Quarter and Full-Year Financial Results Conference Call

GlobeNewswire (Mar 4, 2013)
XOMA to Present at Upcoming Investor Conferences

GlobeNewswire (Feb 21, 2013)
XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris

GlobeNewswire (Jan 7, 2013)
XOMA Selects Non-Infectious Anterior Scleritis as Next Indication in Gevokizumab Proof-of-Concept Program

GlobeNewswire (Dec 31, 2012)
XOMA Appoints Joseph M. Limber to Its Board of Directors

GlobeNewswire (Dec 13, 2012)
XOMA Announces Servier Has Initiated a Proof-of-Concept Gevokizumab Study in Patients With a History of Acute Coronary Syndrome

GlobeNewswire (Nov 29, 2012)
XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial

GlobeNewswire (Nov 20, 2012)
XOMA to Present at Credit Suisse Healthcare Conference

GlobeNewswire (Nov 8, 2012)
XOMA Reports Financial Results for Third Quarter 2012 and Highlights Recent Achievements

GlobeNewswire (Nov 7, 2012)
XOMA to Announce Third Quarter 2012 Financial Results and Host Webcast on November 7

GlobeNewswire (Oct 31, 2012)
XOMA Announces Pricing of $40.0 Million Public Offering of Common Stock

GlobeNewswire (Oct 24, 2012)
XOMA Announces Proposed Public Offering of Common Stock

GlobeNewswire (Oct 23, 2012)
XOMA Initiates Safety and Efficacy Study of Gevokizumab in Patients With Non-Infectious Uveitis Currently Controlled by Systemic Treatment

GlobeNewswire (Oct 3, 2012)
XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis

GlobeNewswire (Sep 27, 2012)

XOMA vs. ETF Alternatives

Company Description

XOMA Ltd. (“XOMA”), a Bermuda company, is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases. Our proprietary development pipeline includes XOMA 052, an... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 12:46 PM Midday top 10 gainers: TRMD +94%. OPTT +42%. VRML +32%. AFFY +28%. TSLA +27%. XOMA +26%. GMCR +25%. CTRP +24%. OWW +23%. CHYR +19%.
Midday top 10 losers: LPSN -34%. PZZI -33%. RAX -26%. KEM -25%. NSYS -23%. MNOV -22%. WG -20%. GV -18%. ORBT -16%. OFIX -16%. Comment! [On the Move]
Thursday, May 9, 10:38 AM XOMA (XOMA +17.9%) goes on a tear this morning after its Q1 results showed its EPS loss narrowing considerably compared to last year. The company also reconfirmed its anticipated cash guidance for ongoing operating activities during 2013 will be approximately $50M, primarily reflecting the costs associated with conducting the Eyeguard Phase 3 clinical trials. Separately, Canaccord ups the shares to Buy, saying it has increased confidence gevokizumab's success based on new supportive Phase 2 data released yesterday. The firm also raised its price target to $8. Comment! [Healthcare, On the Move]
Thursday, May 9, 9:10 AM Premarket gainers: BKS +29%. TSLA +24%. CTRP +17%. GMCR +15%. GRPN +15%. XOMA +12%. TC +12%. OWW +7%. AFFY +7%. WAC +7%.
Losers: LPSN -22%. RAX -21%. PZZI -17%. GV -11%. MNST -10%. SSNC -7%. HEK -7%. 2 Comments [On the Move]
Wednesday, May 8, 6:45 PM XOMA (XOMA): Q1 EPS of -$0.3 misses by $0.10. Revenue of $9.45M beats by $0.85M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, March 12, 4:50 PM XOMA (XOMA): Q4 EPS of $0.03. Revenue of $7.39M misses by $0.48M. Shares +2.3% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Monday, December 31, 2012, 1:13 PM XOMA Corp. (XOMA +1.8%) trades up after saying it's selected active non-infectious anterior scleritis, the inflammation of the fibrous white membrane surrounding the eyeball excluding the cornea, as the third indication in it's proof-of-concept program for gevokizumab. The company will work with the National Eye Institute on designing the study protocol. Comment! [Healthcare, On the Move]
Tuesday, November 20, 2012, 5:39 PM After-hours top gainers, as of 5:15 p.m.: MEMS +83.3%. NAVB +9.7%. VELT +6.9%. XOMA +6.3%. ANFI +6.0%.
After-hours top losers: TLYS -16.9%. ZLC -12.6%. DNDN -3.4%. MBI -2.2%. CHTR -2.1%. Comment! [On the Move]
Wednesday, November 7, 2012, 4:47 PM More on Xoma (XOMA): Q3 comes up shy of both bottom and top line etimates. The company adjusts FY12 guidance due to a rise in anticipated cash used in ongoing operating activities which totalled approximately $40M, up from approximately $35M, due primarily to the decision to defer the licensing and continue the preclinical development of its insulin modulators XMet A and XMet S. Comment! [Healthcare, Earnings]
Wednesday, November 7, 2012, 4:45 PM Xoma (XOMA): Q3 EPS loss of -$0.26 misses by $0.04. Revenue of $7.25M misses by $4.5M. (PR) Comment! [Healthcare, Earnings]
Wednesday, October 24, 2012, 9:10 AM Premarket gainers: SEH +62%. FB +26%. RFMD +14%. LL +13%. RENN +11%. POL +10%. DOW +6%. ZNGA +5%. GRPN +5%. MM +6%.
Losers: TPX -21%. NFLX -18%. DSCO -14%. UTHR -12%. INVN -8%. KMT -7%. XOMA -7%. Comment! [On the Move]
Wednesday, October 24, 2012, 9:10 AM XOMA (XOMA) unveils plans to offer 13.33M shares of common stock at $3/share. The drug maker plans to use proceeds for continued development and testing of its diabetes treatments gevokizumab and XMet platform, as well as for other corporate purposes. XOMA -6.8% premarket. Comment! [Healthcare, On the Move]
Thursday, October 4, 2012, 1:40 PM Xoma (XOMA -1.4%) says it's begun Phase 3 safety and efficacy studies of Gevokizumab, an antibody used to treat diabetes and inflammatory disorders. Comment! [Healthcare]
Thursday, September 27, 2012, 2:36 PM XOMA (XOMA +7.1%) says its partner, Servier has begun phase 3 clinical trials of of Gevokizumab in several European countries. The study is intended to test the efficacy and safety of the drug in the treatment of patients with Behçet's Disease uveitis. Comment! [Healthcare, On the Move]
Wednesday, August 22, 2012, 5:29 PM Xoma (XOMA) receives an Orphan Drug Designation from the FDA for gevokizumab, its IL-1 beta modulating antibody for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis. Shares +2.2% AH. 1 Comment [Healthcare]
Monday, July 30, 2012, 11:27 AM XOMA (XOMA +1.05%) signs a deal for Oncobiologics to use XOMA's ADAPT fully human antibody technology platform to develop drugs for treating cancer and immune diseases. (PR) Comment! [Healthcare]
Friday, July 6, 2012, 12:35 PM Shares of XOMA (XOMA) are active this morning, jumping +13.6% on heavy volume after a bullish article in Seeking Alpha said that with recent management changes the company is better positioned than anytime before to stage a comeback. In addition to new management, its key anti-inflammatory drug, Gevokizumab, is also in Phase III trials and looks very encouraging for wide array of applications. Comment! [Healthcare, On the Move]

007INVESTOR
Traders Get Bullish on Shares of $XOMA http://bit.ly/12sYQ0J
May 14, 6:07 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

007INVESTOR
$XOMA Flying High http://bit.ly/13eLwLa http://bit.ly/15G5N3x
May 13, 1:27 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

007INVESTOR
$XOMA Price Target has been raised from $3.00 to $8.00 From Canaccord Genuity http://bit.ly/10ttUdB
May 9, 9:53 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Kapitall
3 highly shorted stocks being bought by insiders $MCP $SD $XOMA http://seekingalpha.com/a/sydv
Apr 18, 12:17 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

007INVESTOR
Wedbush & Roth Capital Both Have A $5 Price Target On $XOMA http://bit.ly/XnCVUj
Mar 19, 2:00 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

007INVESTOR
$XOMA Upgraded to Outperform at Zacks (XOMA) http://bit.ly/XnCVUj
Mar 19, 1:40 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

smokeyRose
XOMA Hmmmmm Moving up
11/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

nasdaqczar
XOMA Downgraded to Avoid Price Target Set at .50c this thing is a goner more dilution and share sales no hope the pipeline lead drug failed
8/11/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: your track record has been downgraded to avoid. you have no idea what you are talking about.
8/11/12
• !Report Abuse
Add a reply...

140 characters

007INVESTOR
XOMA FRESH AT WORK LOCKING UP NEW PATENTS http://bit.ly/OWILvH
8/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

007INVESTOR
XOMA locked up the Patent for Antibodies on Insulin Receptors XmetA will Replace the Need for Insulin http://bit.ly/N8h1mq
8/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

nasdaqczar
XOMA Downgraded to Avoid Price Target Set at .50c this thing is a goner more dilution and share sales no hope the pipeline lead drug failed
8/11/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: your track record has been downgraded to avoid. you have no idea what you are talking about.
8/11/12
• !Report Abuse
Add a reply...

140 characters

Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh
7/26/12
Reply (5)

• !Report Abuse
View all 5 replies
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
7/26/12
• !Report Abuse
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.
7/26/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
XOMA & Antares Pharma (ATRS) are two high-flying IPOs this year. XOMA's Phase III trials could be promising. http://yhoo.it/Nd7F7p
7/8/12
Reply (1)

• !Report Abuse
View all 1 replies
phemale60: ATRS -- Yayyyyyyyy!! going strong --- thanks Michael, will check out XOMA.
7/9/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Nice rounded bottom in XOMA stock. http://yhoo.it/xJNzCG
7/4/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: in January??
7/4/12
• !Report Abuse
Michael Bryant: No, in May.
7/4/12
• !Report Abuse
Add a reply...

140 characters

XOMA XOMA Ltd.

XOMA

XOMA Ltd.